Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of [11C]MC1 PET in Musculoskeletal Conditions
NCT03912428Phase 1Terminated
- Sponsor
- National Institute of Mental Health
- Start
- Jun 2019
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [11C]MC1 in rheumatoid arthritis (RA), idiopathic inflammatory myopathy (IIM) and axial spondyloarthritis (axSpA) (5 arms), sponsored by National Institute of Mental Health. Primary endpoints: Uptake of [11C]MC1 by Organs at 120 months, Uptake of [11C]MC1 by Organs - Gender Specific Organs at 120 months and 5 more. Started Jun 2019; status: terminated.
02
Drugs
[11C]MC1
03
Conditions
rheumatoid arthritis (RA)idiopathic inflammatory myopathy (IIM)axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT03912428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03912428.